Imaging Biometrics, LLC, a subsidiary of IQ-AI Limited, is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated
MILWAUKEE, WI / ACCESSWIRE / March 7, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
The paper, published in Frontiers in Oncology, was written by a team of clinicians, engineers, and physicists working on behalf of the European Cooperation in Science and Technology (COST) Glioma MR Imaging 2.0 (GLiMR) Initiative. It consisted of a comprehensive review of advanced MRI techniques used in Europe for monitoring treatment response in high-grade brain tumors. The authors of the study concluded that dynamic susceptibility contrast (DSC) MRI is the most proven of all advanced methods. IB’s software modules, IB Neuro™ and IB DCE™, provided solutions for analysis of this data, with examples from each included in the paper.
The study acknowledged the limitations and challenges presented with conventional MRI and specifically noted the quantitative technology contained in IB Neuro termed “standardization.” This exclusive technology is built into IB Neuro and automatically generates standardized relative cerebral blood volume (sRCBV) maps. And, as the paper cites, IB Neuro’s sRCBV has demonstrated greater consistency and improved repeatability over the inherently variable and manual “tissue normalization” approaches.
“Standardization is significant because it allows for direct comparison between scans independent of MR scanner platform, field strength, or patient,” said Michael Schmainda, CEO of IB. “This paper nicely summarizes the advancements made over the years in advanced MRI techniques, and we are pleased that the sRCBV technology available in IB Neuro was highlighted.”
About IQ-AI Limited
IQ-AI Limited, (LON:IQAI) (OTCQB:IQAIF), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com.
Safe Harbor Statement
This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” or the negative of these words and/or similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forwardlooking statements involve inherent risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. For example, statements about future revenues and the Company’s ability to fund its operations and contractual obligations are forward looking and subject to risks. Several important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, the inability to raise capital to support the Company through its growth stage, the Company’s inability to generate projected sales and trade relations between the United States and China. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact:
Michael Porter, President
Porter, LeVay & Rose, Inc.
Tel: 212-564-4700
mike@plrinvest.com
SOURCE: IQ AI Ltd.
View source version on accesswire.com:
https://www.accesswire.com/691832/Imaging-Biometrics-Touts-Position-Paper-for-Monitoring-High-Grade-Glioma-Treatment-Response
